Migraleve Yellow tablets contain paracetamol 500mg and codeine phosphate 8mg per tablet for pain relief during migraine attacks in adults and young people aged 12 and over.
Available as a pharmacy medicine (P) without a prescription, they are the follow-on analgesic component of the Migraleve dual-pack system, used after Migraleve Pink tablets once nausea has subsided.
They can also be used independently for migraine attacks where nausea is not a significant feature. The 24-tablet pack provides a practical short-course supply.
Courier Pharmacy provides expert pharmacist guidance to help you use Migraleve Yellow safely within your migraine management plan.
Migraleve Yellow Tablets provide follow-on pain relief within the Migraleve migraine system. Each film-coated tablet contains paracetamol 500mg and codeine phosphate 8mg. So, it offers stronger pain relief than paracetamol alone for some people.
Paracetamol helps to reduce pain and fever. Meanwhile, codeine adds an opioid-based pain relief layer, which can extend the effect when a migraine won’t budge. In other words, Migraleve Yellow focuses on pain control.
Unlike Migraleve Pink Tablets, Migraleve Yellow Tablets contain no anti-sickness ingredient. Migraleve Pink includes buclizine hydrochloride 6.25mg, which targets nausea and vomiting. Because Migraleve Yellow has no antiemetic, it usually suits the stage of a migraine when nausea has eased and you mainly need ongoing pain relief.
The Migraleve system works as a pair. You take pink tablets at the first sign of a migraine, when nausea is more likely. Then you use yellow tablets for later doses, when you no longer need the anti-sickness component. As a result, the two-colour approach can cover more of the “full migraine” experience than either colour alone.
That said, you can also use Migraleve Yellow Tablets on their own. For example, they may suit people whose migraines don’t usually cause much nausea, or when nausea has already settled before treatment.
Migraleve Yellow Tablets are a pharmacy medicine (P), so you need to buy them from a registered pharmacy. This is mainly because they contain codeine, which can cause dependence if you use it too often. For that reason, a pharmacist will check it’s appropriate and safe for you. Our pharmacists at Courier Pharmacy treat this as a real clinical chat, not a tick-box exercise.
Migraleve Yellow Tablets are manufactured by McNeil Products Limited and supplied in a 24-tablet pack.
Key features and specifications
Active ingredients (per tablet): Paracetamol 500mg, Codeine phosphate 8mg
No antiemetic: No buclizine (unlike Migraleve Pink Tablets, which contain buclizine 6.25mg)
Pack size: 24 tablets
Legal category: Pharmacy medicine (P)
Suitable for: Adults and young people aged 12 and over
Licensed indication: Treatment of migraine (as follow-on analgesic in the Migraleve system, or as a standalone option where nausea is absent)
Maximum use: Up to three consecutive days
MOJO WISDOM
Take control of your health by understanding your condition and what this medication is doing for you.
READ:
More information about this treatment.
UK-based doctors and pharmacists
Discreet and Confidential
UK-based doctors and pharmacists
Free, Expert Advice
No video link provided.
No video link provided.
UK-based doctors and pharmacists
Free, expert advice
Discrete and confidential
Fast delivery
Giving you trusted clinical advice for over 40 conditions
A UK regulated pharmacy providing safe, effective treatments online since 2014
Once the nausea has settled, the pain needs to keep being managed — Migraleve Yellow tablets are designed for exactly that moment
Migraine attacks often have two distinct phases of suffering. The first, most acute phase comes with nausea, light sensitivity, and throbbing pain all arriving together; this is where Migraleve Pink tablets, with their antiemetic buclizine component, are designed to act. But once the nausea has subsided and the attack is continuing, you need sustained pain relief without the sedating antihistamine. That is the clinical purpose of Migraleve Yellow tablets.
Each tablet contains paracetamol 500mg and codeine phosphate 8mg, providing central and opioid-pathway analgesia to carry you through the remaining hours of a migraine attack. Available as a pharmacy medicine (P) without a prescription, Migraleve Yellow tablets are the second part of the Migraleve dual-pack system.
At Courier Pharmacy, we believe healthcare should fit the person. For people living with migraine, including those managing it alongside general chronic illness or CFS/ME, having a pharmacist team that understands your full picture makes the difference between generic advice and genuinely useful guidance.
Five things worth knowing straight away
Migraleve Yellow tablets contain paracetamol 500mg and codeine phosphate 8mg per tablet; they do not contain buclizine, making them distinct from Migraleve Pink tablets which include an antiemetic.
They are a pharmacy medicine (P), available without a prescription but only from a registered pharmacy under pharmacist supervision.
Migraleve Yellow is typically used as follow-on analgesia after initial Migraleve Pink tablets, once nausea has settled and sustained pain relief is still needed.
Codeine phosphate carries a risk of dependence; Migraleve Yellow tablets must not be used for more than three consecutive days, and the total use pattern across the Pink and Yellow system must be factored into the three-day limit.
Not suitable for children under 12, known ultra-rapid codeine metabolisers, or those who are pregnant or breastfeeding.
Treatment dosage: Migraleve Yellow tablets
For adults and young people aged 16 and over: take one to two tablets every four to six hours as needed, up to a maximum of eight tablets in any 24-hour period. For young people aged 12 to 15: take one tablet every six hours as needed, maximum four tablets in 24 hours. Do not give Migraleve Yellow to children under 12 years of age.
When using as part of the Migraleve dual-pack system: take two Migraleve Pink tablets at the first sign of the attack. If further pain relief is needed as the attack continues, take one to two Migraleve Yellow tablets every four to six hours (or one tablet every six hours for 12 to 15 year olds). The total number of tablets across the Pink and Yellow system in 24 hours should not exceed eight tablets for adults and four for young people aged 12 to 15. Swallow tablets whole with a full glass of water.
Do not use Migraleve Yellow tablets for more than three consecutive days. If your migraine is not responding within this timeframe or if attacks are becoming more frequent, seek pharmacist or GP advice rather than continuing OTC analgesic use. Using analgesics, including codeine-containing products, on more than ten days per month is the threshold above which medication overuse headache becomes a clinically significant risk.
Overview of Migraleve Yellow tablets
The Migraleve system as a whole reflects a thoughtful clinical design. Migraine is not a uniform event; its symptom profile changes as the attack progresses. During the acute onset phase, nausea is not just uncomfortable in itself, it also impairs the absorption of oral analgesics by causing gastric stasis and increasing the likelihood of vomiting before the tablet can be absorbed. The Pink tablet’s buclizine component addresses this directly. As the attack matures and nausea fades, the requirement changes from antiemetic plus analgesic to analgesic alone. Yellow tablets are designed for this second phase.
People who use Migraleve Yellow tablets independently, without the Pink, are typically those whose migraine attacks arrive without significant nausea, or those who have already managed the initial nausea with a non-pharmacological approach or an anti-nausea medicine taken separately. This is entirely clinically appropriate. If your migraine pattern does not include nausea, or if nausea is mild and self-limiting, using co-codamol 8/500mg (which is pharmacologically identical to Migraleve Yellow) or Migraleve Yellow alone is a reasonable acute treatment option.
Medicine overuse headache
The medication overuse headache risk deserves particular attention in the context of migraine management because migraine sufferers are, by definition, more likely than the general population to use acute analgesics frequently. MOH, sometimes called analgesic rebound headache, occurs when regular analgesic use causes the brain to become more sensitised to pain signals, ultimately producing more frequent and more severe headaches. The codeine component of Migraleve Yellow is particularly relevant here; opioid-containing analgesics carry a higher MOH risk than paracetamol or NSAIDs alone. If you are using any acute migraine medicine more than ten days per month, a preventive migraine treatment conversation with your GP is more clinically valuable than increasing OTC analgesic use.
For people managing migraine alongside other chronic conditions, including CFS/ME or fibromyalgia where pain sensitivity is already altered and sleep disruption is an issue, the codeine component’s mild sedating properties may be an occasional practical advantage or a practical concern, depending on when the migraine occurs and what other demands are present. Our pharmacists at Courier Pharmacy can discuss whether Migraleve Yellow or an alternative acute analgesic best fits your specific pattern and lifestyle.
3 day limit
The three-day limit for Migraleve Yellow, as with all codeine-containing products, is a firm clinical boundary rather than a conservative guideline. Physical dependence on codeine can begin to develop with surprisingly short periods of regular use. If stopping after a three-day course feels harder than expected, if there is a strong urge to continue, or if symptoms seem worse when you stop rather than better, these are signs worth discussing with your pharmacist or GP promptly.
Why choose Courier Pharmacy for Migraleve Yellow tablets
At Courier Pharmacy, we think healthcare should fit the person. For migraine sufferers, that means being taken seriously, given honest information about your options, and supported rather than handed a product with a nod and a receipt.
Our service is shaped by the philosophy of Dr Ada Jex-Cori, our brand pharmacist, who built her practice on the idea that expert, personalised care should be accessible to everyone. Her message, that you are not broken and the system is the problem we are here to fix, resonates especially with people who have been managing migraine for years without the level of support that would genuinely help.
For people managing migraine alongside other chronic conditions, including CFS/ME, fibromyalgia, or conditions where pain sensitivity is already altered, the choice of acute migraine treatment, including whether the antiemetic component is needed for a given attack and whether the codeine contribution is helpful or not, is worth discussing properly. Our pharmacists can help you think through whether Migraleve Yellow alone, Migraleve Pink and Yellow together, or an entirely different approach better fits your migraine pattern.
Trust is earned through transparency and consistency. Courier Pharmacy is GPhC-regulated, grounds all clinical content in NHS, NICE, BNF, and peer-reviewed evidence, and will tell you clearly when Migraleve Yellow is not appropriate for your situation. If something else would serve you better, we will say so.
Buy Migraleve Yellow tablets from Courier Pharmacy
Migraleve Yellow tablets are a pharmacy medicine (P). They do not require a prescription, but they must be purchased from a registered pharmacy under pharmacist supervision. Our team will confirm suitability before your order is processed.
Here is how our service works:
Browse and select Migraleve Yellow tablets from our online store.
Complete a brief online consultation confirming the product is appropriate for your situation.
A member of our pharmacy team reviews your answers and confirms your order.
We dispense and deliver discreetly to your door.
If Migraleve Yellow tablets are not suitable for you, we will explain why and suggest the next best option. We would rather give you the right treatment than a quick sale.
Our free fortnightly drop-in clinics at Insomnia, Derby run every other fortnight from 12 to 1pm. Migraine management, understanding the Pink and Yellow system, medication overuse headache, and knowing when to consider preventive treatment are all topics we cover regularly. No appointment, no charge, no pressure.
Summary
Migraleve Yellow tablets are pharmacologically identical to standard co-codamol 8/500mg tablets; the clinical distinction is their specific licensed indication for migraine and their position within the Migraleve dual-system alongside the antiemetic-containing Pink tablets.
The absence of buclizine in Migraleve Yellow is intentional; once nausea has settled, continued antihistamine exposure adds sedation without benefit, and Yellow tablets allow ongoing analgesia without the drowsiness that buclizine contributes.
Codeine is a prodrug that requires conversion to morphine by the liver enzyme CYP2D6; poor metabolisers produce very little morphine and may find the codeine component provides minimal additional benefit, while ultra-rapid metabolisers are at risk of morphine toxicity and should not use codeine-containing products.
Medication overuse headache (MOH) is a specific and well-documented risk for migraine sufferers using analgesics frequently; using any acute migraine medicine, including Migraleve Yellow, on more than ten days per month is the threshold above which MOH becomes a clinically significant concern.
For people using Migraleve Yellow independently (without the Pink), the 24-tablet pack provides twelve two-tablet doses, which is ten months of supply if used for one typical migraine attack per month — or just over three standard dosing courses if attacks are longer.
Active ingredients in Migraleve Yellow tablets
Each Migraleve Yellow tablet contains two active ingredients. Paracetamol 500mg is a centrally acting analgesic and antipyretic that raises the pain threshold in the brain and spinal cord through inhibition of a central cyclo-oxygenase isoform and modulation of serotonergic descending pain pathways. It also reduces fever by acting on the hypothalamic thermoregulatory set-point.
At 500mg, this is the standard full analgesic dose of paracetamol and provides a meaningful central contribution to migraine pain relief. Codeine phosphate 8mg is an opioid prodrug that is converted to morphine by the liver enzyme CYP2D6. Morphine binds to mu-opioid receptors in the brain, spinal cord, and peripheral tissues, reducing pain signal transmission and altering the emotional response to pain. At 8mg, the morphine produced is modest but clinically additive to paracetamol's central analgesic effect.
The formulation does not contain buclizine or any other antiemetic, which is the defining difference from Migraleve Pink tablets. This is a deliberate pharmaceutical decision: Yellow tablets are designed for the phase of a migraine attack when nausea is no longer the primary symptom, and the analgesic combination without sedating antihistamine provides cleaner pain coverage for people who need to continue functioning as the attack subsides.
What are Migraleve Yellow tablets used for?
Migraleve Yellow tablets are specifically licensed for the treatment of migraine in adults and young people aged 12 and over. They are used as the analgesic follow-on component within the Migraleve dual-pack system, taken after Migraleve Pink tablets when nausea has settled and continued pain relief is needed. They can also be used independently for migraine attacks that do not involve significant nausea or where nausea has resolved before the first dose is needed.
The product is designed for acute migraine attack management, not for migraine prevention. Taking Migraleve Yellow tablets does not reduce the frequency of future attacks; it addresses the pain of the current one. If migraine attacks are occurring frequently enough that acute OTC management feels like the only tool available, this is a signal to discuss preventive treatment with a GP. Preventive options including beta-blockers, topiramate, amitriptyline, and the newer CGRP antagonists can dramatically reduce attack frequency for some people.
Migraleve Yellow is not appropriate for tension headache, cluster headache, or non-migraine pain. The codeine component adds meaningful benefit for migraine specifically, but using it regularly for non-migraine headaches increases the risk of medication overuse headache and is clinically unjustified. If you are not sure whether your headaches are migraines, a pharmacist or GP conversation about headache diagnosis is worthwhile before committing to a migraine-specific treatment regimen.
How do Migraleve Yellow tablets work?
Paracetamol raises the pain threshold centrally by inhibiting a variant of the cyclo-oxygenase enzyme in neural tissue, reducing prostaglandin synthesis in the brain and spinal cord. This reduces the central sensitisation that amplifies pain signals during a migraine attack. Paracetamol also has modulatory effects on the descending serotonergic pain pathways that run from the brainstem to the spinal cord, providing additional analgesic contribution through a mechanism that complements COX inhibition. Its antipyretic action is relevant for migraine attacks accompanied by a low-grade fever or heat sensitivity.
Codeine phosphate is a prodrug that exerts its analgesic effect primarily through conversion to morphine in the liver by the CYP2D6 enzyme. Morphine then binds to mu-opioid receptors throughout the central and peripheral nervous system, inhibiting pain signal transmission at multiple points in the nociceptive pathway. In the dorsal horn of the spinal cord, mu-opioid receptor activation reduces the transmission of afferent pain signals to the brain. In the brain itself, morphine alters the emotional valence of pain, reducing its perceived severity and the suffering it causes even when the pain stimulus itself persists. At the 8mg codeine dose in Migraleve Yellow, the morphine produced is modest but provides a meaningful analgesic step-up beyond paracetamol alone.
The pathophysiology of migraine involves sensitisation of trigeminal nerve pathways, release of neuropeptides including calcitonin gene-related peptide (CGRP), and both peripheral and central sensitisation that amplifies pain perception. Migraleve Yellow addresses the pain through central analgesic mechanisms at both paracetamol's serotonergic-COX level and codeine's opioid receptor level. These mechanisms are separate from the specific trigeminovascular mechanism targeted by triptans; Migraleve Yellow is a symptom-based analgesic rather than a migraine-specific pharmacological intervention. This means it may work less reliably than triptans for moderate to severe migraine with a clear trigeminovascular component, which is a clinically relevant point for people deciding between OTC analgesic management and prescription migraine-specific treatment.
The absence of buclizine distinguishes the mechanism of Migraleve Yellow from Migraleve Pink in a pharmacologically meaningful way. With buclizine absent, there is no antihistamine contribution and no associated sedation. This means Migraleve Yellow is more appropriate than Pink for daytime use when alertness is needed, or when the patient is driving or needs to remain functional while managing the later phase of an attack. The analgesic coverage is equivalent to the analgesic components of Pink; the absence of sedation from buclizine is the practical distinction.
How to use Migraleve Yellow tablets
Take one to two tablets with a full glass of water every four to six hours as needed. Migraleve Yellow tablets can be taken with or without food; taking them after a small amount of food reduces any potential nausea from the codeine component. If you are using the full Migraleve system: start with two Pink tablets at the first sign of the attack, then switch to Yellow tablets for subsequent doses once nausea has settled. If you are using Yellow tablets independently: take them at the onset of pain or as soon as it is clear that a migraine is developing.
Check everything else you are taking for paracetamol content before each dose. Migraleve Yellow already contains 500mg of paracetamol per tablet; at two tablets per dose, this is 1000mg, and at the maximum four doses per day this is 4000mg, the full safe daily maximum. Any other paracetamol-containing product taken on the same day must be counted against this limit. Cold and flu remedies, night-time pain tablets, and many combination OTC products contain paracetamol. Accidental paracetamol overdose from combining products is one of the most common and most preventable causes of serious liver injury.
Keep a record of how many days per month you use Migraleve Yellow or any other acute migraine medicine. If you are reaching for it on more than ten days per month, that number is the signal to have a conversation with your GP about preventive migraine treatment rather than escalating OTC use. The three-day limit per attack is also firm: if your migraine is still significantly debilitating after three days of analgesic treatment, that is a signal for medical assessment, not continued OTC management.
Warnings and precautions for Migraleve Yellow tablets
Do not give Migraleve Yellow to children under 12 years of age. Codeine phosphate is contraindicated in under-12s following MHRA guidance due to the risk of respiratory depression, particularly in children who are ultra-rapid codeine metabolisers. For young people aged 12 to 15, the reduced dose of one tablet every six hours applies and the three-day limit is equally firm. Do not use if you are allergic to paracetamol, codeine phosphate, or any other ingredient in the tablets.
Ultra-rapid codeine metabolisers must not use Migraleve Yellow. People who carry CYP2D6 gene variants causing accelerated conversion of codeine to morphine produce excessive morphine levels from standard doses, creating a risk of opioid toxicity including severe drowsiness, slowed breathing, and confusion. If you have ever been told you are an ultra-rapid codeine metaboliser, or if you have experienced an unusually strong or concerning response to codeine in the past, do not use Migraleve Yellow and discuss alternative analgesics with your pharmacist or prescriber.
Codeine dependence is a real risk even with short-course use at OTC doses. The three-day maximum is a clinical boundary, not a conservative suggestion. People with a personal or family history of substance misuse or addiction should discuss codeine-containing products carefully with their pharmacist before purchase. If stopping Migraleve Yellow after a course feels difficult, or if there is a compulsion to take more or more frequently than directed, speak to your pharmacist or GP promptly.
Do not take Migraleve Yellow alongside other paracetamol-containing products without carefully calculating the combined daily total. The maximum safe adult dose of paracetamol is 4000mg per day. Paracetamol overdose, even at modest levels above the safe limit sustained over several days, can cause serious and irreversible liver damage. If you have accidentally taken more paracetamol than the recommended amount from all sources, seek emergency medical attention immediately even if you feel well, as serious liver damage may develop 24 to 48 hours later with minimal early symptoms.
Pregnancy and breastfeeding: codeine is contraindicated during pregnancy, particularly in the third trimester, and should not be taken by breastfeeding mothers. If the mother is an ultra-rapid codeine metaboliser, the infant can receive toxic morphine levels through breast milk. If you are pregnant or breastfeeding and need analgesic treatment for migraine, paracetamol alone is the recommended first-line option; speak to your midwife or GP for personalised advice before taking any codeine-containing product.
Side effects of Migraleve Yellow tablets
The most predictable side effects of Migraleve Yellow relate to its codeine component. Constipation is the most frequently reported effect and affects the majority of people who take codeine-containing medicines, even briefly. Staying well hydrated and maintaining fibre intake during a migraine course helps. Nausea and vomiting, somewhat paradoxically for a product used after nausea has settled, can occur with codeine, particularly at higher doses. Taking the tablets after a small amount of food reduces this risk.
Less common side effects include drowsiness or lightheadedness, dry mouth, dizziness, and headache (which can be difficult to distinguish from the migraine itself). A mild euphoric or pleasant sensation with the codeine component can occur; this is part of why codeine carries misuse potential and reinforces the importance of the three-day limit. Skin reactions including rash or itching can occur in people with sensitivities to either active ingredient.
Rare but serious side effects include severe allergic reactions including anaphylaxis, respiratory depression particularly in ultra-rapid metabolisers or in overdose, serious liver damage from paracetamol toxicity if the recommended dose is exceeded, and blood disorders. If you develop difficulty breathing, severe rash, confusion, or signs of liver problems including jaundice (yellowing of the skin or whites of the eyes) during treatment, seek emergency medical attention immediately.
Report suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Patient reports are an important part of ongoing medicines safety monitoring.
Drug interactions with Migraleve Yellow tablets
The interaction profile of Migraleve Yellow spans both active ingredients. Tell your pharmacist about all medicines you are taking before purchasing, including prescription medicines, OTC products, and herbal remedies.
Other paracetamol-containing products are the most clinically significant interaction in everyday use. A large number of OTC medicines contain paracetamol, and combining them with Migraleve Yellow (which provides 500mg per tablet) can easily push the daily total above the safe limit of 4000mg. Check the ingredients of every medicine you are taking on the same day as Migraleve Yellow, particularly cold and flu remedies, night-time pain products, and other combination analgesics.
CNS depressants interact with the codeine component by additive sedation and respiratory depression. This group includes alcohol, benzodiazepines, other opioids, sedating antihistamines (found in some sleep aids and allergy medicines), and certain antidepressants and antipsychotics. Combining codeine with any of these increases the risk of excessive sedation and in severe cases respiratory depression. Avoid alcohol completely during any course of Migraleve Yellow. Notably, Migraleve Pink already contains buclizine, a sedating antihistamine; if transitioning from Pink to Yellow tablets, the cumulative sedation from the Pink dose earlier in the day should be borne in mind.
Monoamine oxidase inhibitors (MAOIs) are contraindicated with codeine and should not be taken concurrently or within 14 days of stopping an MAOI. Triptans and serotonergic medicines taken alongside codeine at higher doses carry a theoretical serotonin syndrome risk, though this is unlikely at 8mg. SSRIs taken alongside paracetamol and codeine combination products may increase GI bleeding risk modestly, through reduction in serotonin-mediated platelet aggregation. Warfarin and other anticoagulants may have their effect enhanced by regular high-dose paracetamol use; for a typical migraine course this is unlikely to be significant, but regular users should inform their anticoagulation clinic of any consistent analgesic use.
Frequently asked questions about Migraleve Yellow tablets
What are Migraleve Yellow tablets used for?
Migraleve Yellow tablets are used for pain relief during migraine attacks in adults and young people aged 12 and over. Each tablet contains paracetamol 500mg and codeine phosphate 8mg. They are used as follow-on pain relief after Migraleve Pink tablets once nausea has settled, or independently for attacks without significant nausea. They are a pharmacy medicine available without a prescription.
What is the difference between Migraleve Yellow and Migraleve Pink tablets?
The key difference is that Migraleve Pink contains buclizine hydrochloride 6.25mg, a sedating antihistamine with antiemetic properties, in addition to paracetamol and codeine. Migraleve Yellow contains only paracetamol and codeine, with no antiemetic. Pink tablets are designed for the onset of an attack when nausea is present; Yellow tablets are for subsequent doses once nausea has resolved, providing analgesic coverage without additional sedation from buclizine.
Can I take Migraleve Yellow without Migraleve Pink?
Yes. If your migraine attacks do not typically include significant nausea, or if nausea has already resolved before you take the first dose, Migraleve Yellow alone is an appropriate treatment. It provides the same analgesic content as the combination system, simply without the buclizine antiemetic. Many people find this simpler and more suitable for daytime use when alertness matters.
How many Migraleve Yellow tablets can I take at once?
Adults and young people aged 16 and over may take one to two tablets every four to six hours, up to a maximum of eight tablets in 24 hours. Young people aged 12 to 15 should take one tablet every six hours, maximum four in 24 hours. Do not exceed these limits and do not use for more than three consecutive days.
Can Migraleve Yellow tablets cause dependence?
Yes. The codeine component has dependence potential with regular use. Within a properly observed three-day course, the risk is low for most people but is not zero. Frequent use beyond the three-day limit, or use on many days per month, significantly increases dependence risk. If stopping feels difficult or if you feel you need the tablets more often than directed, speak to your pharmacist or GP.
What is medication overuse headache and does it apply to Migraleve Yellow?
Medication overuse headache (MOH) develops when analgesics are used on more than ten to fifteen days per month. The brain adapts to regular analgesic exposure and becomes more pain-sensitive, paradoxically worsening headache frequency and severity over time. This applies to any acute migraine medicine including Migraleve Yellow. If you are using acute analgesics for migraine this frequently, a GP conversation about preventive treatment is more appropriate than continued OTC escalation.
Is Migraleve Yellow the same as co-codamol?
The active ingredients are identical: paracetamol 500mg and codeine phosphate 8mg per tablet. This is the same combination as co-codamol 8/500mg. The distinction is that Migraleve Yellow has a specific licensed indication for migraine, and is part of the Migraleve dual-system designed for migraine management. For everyday pain outside of migraine, standard co-codamol 8/500mg is equivalent.
Can I take Migraleve Yellow if I am on antidepressants?
This depends on the type of antidepressant. MAOIs are contraindicated with codeine and cannot be combined with Migraleve Yellow or taken within 14 days of stopping one. SSRIs and SNRIs can modestly increase GI bleeding risk when combined with paracetamol and codeine. Tricyclic antidepressants add to codeine's sedative effects. Discuss Migraleve Yellow with your pharmacist if you take any antidepressant before purchasing.
Can I drive after taking Migraleve Yellow tablets?
Codeine can cause drowsiness, dizziness, and impaired concentration. You should not drive or operate heavy machinery until you know how Migraleve Yellow affects you. Without the additional buclizine antihistamine of Migraleve Pink, the sedative effect is somewhat less than the full Migraleve system, but codeine alone is still capable of impairing driving ability. Under UK law, driving with codeine above specified limits is a criminal offence even when taken as directed.
What should I do if I accidentally take too much Migraleve Yellow?
Seek emergency medical attention immediately, even if you feel well. Paracetamol overdose can cause serious liver damage that may not produce obvious symptoms for 24 to 48 hours after ingestion. Do not wait to see if symptoms develop. Call 999 or go to your nearest emergency department and take the packaging so healthcare staff know exactly what was taken and in what quantity.
Can Migraleve Yellow be used for tension headache?
Migraleve Yellow is licensed specifically for migraine and should not be used as a routine treatment for tension headache. Using codeine-containing products regularly for tension headache significantly increases the risk of medication overuse headache without the specific benefit that makes codeine an appropriate addition to migraine treatment. For tension headache, paracetamol or ibuprofen alone is the appropriate first choice.
Is Migraleve Yellow suitable for children?
Migraleve Yellow is not suitable for children under 12. For young people aged 12 to 15, the dose is one tablet every six hours, maximum four tablets in 24 hours, and use must not exceed three consecutive days. Codeine is contraindicated in under-12s following MHRA guidance due to the risk of respiratory depression, particularly in children who are ultra-rapid codeine metabolisers.
How does Migraleve Yellow compare to taking paracetamol and codeine separately?
Migraleve Yellow contains paracetamol 500mg and codeine 8mg per tablet in a convenient pre-combined formulation specifically indicated for migraine. Taking separate paracetamol and codeine tablets would provide equivalent active ingredient doses if chosen at the same strengths. The advantage of Migraleve Yellow is the migraine-specific packaging and dosing system alongside the complementary Pink antiemetic tablets, making it practical for attack management without the need to manage multiple separate products.
What is an ultra-rapid codeine metaboliser and why does it matter for Migraleve Yellow?
Ultra-rapid metabolisers carry a gene variant causing them to convert codeine to morphine much faster and in larger quantities than normal. Even standard doses can produce morphine levels high enough to cause toxicity, including severe drowsiness, slow breathing, and confusion. Ultra-rapid metabolisers should not use Migraleve Yellow or any codeine-containing product. This genetic variant is more common in people from certain ethnic backgrounds; genetic testing for metaboliser status is available where clinically indicated.
Can Migraleve Yellow help with migraine aura?
Migraleve Yellow does not affect the aura phase of migraine; aura is a neurological phenomenon involving cortical spreading depolarisation that is not directly affected by analgesics or antiemetics. Taking Migraleve Yellow during aura may help position the analgesic effect ahead of the pain phase if aura reliably predicts pain onset for you, and it is reasonable to take an analgesic dose at the start of aura if that is your typical migraine pattern. For aura-triggered strategies, discuss timing with your pharmacist.
Can Migraleve Yellow cause constipation?
Yes. Constipation is one of the most predictable effects of codeine, affecting the majority of people who take opioid-containing medicines. Codeine slows intestinal motility through opioid receptors in the gastrointestinal tract. For a three-day migraine course, maintaining adequate fluid intake and dietary fibre usually manages this effectively. If constipation is already a concern for you, discuss whether a codeine-free alternative analgesic would better suit your needs.
Should Migraleve Yellow be taken with food?
Migraleve Yellow can be taken with or without food. Taking it after a small amount of food reduces the likelihood of nausea from the codeine component, which can occasionally cause gastric discomfort on an empty stomach. During a migraine attack, the reduced gastric motility (gastric stasis) that often accompanies the attack may also slow absorption; taking with a small amount of food may modestly reduce this effect.
How do I know when to switch from Migraleve Pink to Migraleve Yellow?
Switch to Yellow tablets when the nausea component of your attack has clearly settled and you only need continued analgesia. For most people this is apparent within the first one to two hours of the attack; the nausea typically improves as the antiemetic from the Pink dose takes effect. If nausea is still significant after the Pink dose, you can take a second dose of Pink before switching to Yellow; the dosing schedule for the full system specifies when subsequent doses can be taken.
Disclaimer: This article is for general information only and isn’t a substitute for personal medical advice, diagnosis, or treatment. Always check with a GP, pharmacist, or specialist before starting a new supplement if you have a medical condition or take regular medicines.
